TLR5, 7, 8, and 9 correlate with better clinical outcomes (high immune cell marker expression and/or longer survival), while TLR4, 7, and 9 are associated with poorer outcomes (advanced tumor stage, poor differenciation, and shorter survival) (252). This evidence concerns the gene TLR5 and neoplasm.